• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by The Cooper Companies Inc.

    2/14/24 10:04:33 AM ET
    $COO
    Ophthalmic Goods
    Health Care
    Get the next $COO alert in real time by email
    SC 13G 1 coo13gdec23.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) COOPER COS INC/THE (Name of Issuer) COMMON STOCK (Title of Class of Securities) 216648402 (CUSIP NUMBER) December 31, 2023 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. Rowe Price Investment Management, Inc. 85-4328500 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 838,168 6. Shared Voting Power* 0 7. Sole Dispositive Power* 1,904,963 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,834,491 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 3.7% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: COOPER COS INC/THE Item 1(b) Address of Issuer's Principal Executive Offices: 6101 BOLLINGER CANYON ROAD, SUITE 500, SAN RAMON, CALIFORNIA 94583 Item 2(a) Name of Person(s) Filing: (1) T. Rowe Price Investment Management, Inc. (Price Investment Management) Item 2(b) Address of Principal Business Office: 101 E. Pratt Street, Baltimore, MD 21201 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 216648402 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class This statement is being filed to report the fact that, as of the date of this report, the reporting person(s) has (have) ceased to be the beneficial owner of more than five percent of the class of securities. Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Investment Management does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Investment Management serves as investment adviser. Any and all discretionary authority which has been delegated to Price Investment Management may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Investment Management which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Investment Management. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. Rowe Price Investment Management, Inc. Date: February 14, 2024 Signature: /s/ Armando Capasso Name & Title: Armando Capasso, Vice President 12/31/2023
    Get the next $COO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COO

    DatePrice TargetRatingAnalyst
    6/17/2025$94.00Hold → Buy
    Needham
    5/30/2025$76.00Overweight → Neutral
    Analyst
    8/29/2024$115.00 → $120.00Overweight
    Piper Sandler
    7/16/2024$107.00 → $115.00Hold → Buy
    Jefferies
    3/19/2024$125.00Neutral → Buy
    Redburn Atlantic
    3/13/2024$100.00 → $120.00Neutral → Overweight
    JP Morgan
    2/6/2024Sector Weight
    KeyBanc Capital Markets
    10/30/2023$380.00Buy
    BofA Securities
    More analyst ratings

    $COO
    SEC Filings

    See more
    • SEC Form SD filed by The Cooper Companies Inc.

      SD - COOPER COMPANIES, INC. (0000711404) (Filer)

      5/30/25 4:20:18 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form 10-Q filed by The Cooper Companies Inc.

      10-Q - COOPER COMPANIES, INC. (0000711404) (Filer)

      5/30/25 4:19:23 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form 8-K filed by The Cooper Companies Inc.

      8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

      5/29/25 4:31:50 PM ET
      $COO
      Ophthalmic Goods
      Health Care

    $COO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Carbone Barbara

      4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

      5/5/25 4:16:23 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form 3 filed by new insider Carbone Barbara

      3 - COOPER COMPANIES, INC. (0000711404) (Issuer)

      5/5/25 4:14:05 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Director Kozy William A converted options into 2,857 shares, increasing direct ownership by 10% to 31,149 units (SEC Form 4)

      4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

      4/3/25 4:09:38 PM ET
      $COO
      Ophthalmic Goods
      Health Care

    $COO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cooper upgraded by Needham with a new price target

      Needham upgraded Cooper from Hold to Buy and set a new price target of $94.00

      6/17/25 7:46:56 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Cooper downgraded by Analyst with a new price target

      Analyst downgraded Cooper from Overweight to Neutral and set a new price target of $76.00

      5/30/25 8:39:00 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Piper Sandler reiterated coverage on Cooper with a new price target

      Piper Sandler reiterated coverage of Cooper with a rating of Overweight and set a new price target of $120.00 from $115.00 previously

      8/29/24 8:24:13 AM ET
      $COO
      Ophthalmic Goods
      Health Care

    $COO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CooperCompanies Announces Second Quarter 2025 Results

      SAN RAMON, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2025. Revenue increased 6% year-over-year to $1,002.3 million. CooperVision (CVI) revenue up 5% to $669.6 million, and CooperSurgical (CSI) revenue up 8% to $332.7 million.GAAP diluted earnings per share (EPS) of $0.44, consistent with last year's second quarter.Non-GAAP diluted EPS of $0.96, up $0.11 or 14% from last year's second quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, CooperCompanies' President and CEO said,

      5/29/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies' 2024 Sustainability Report Showcases Efforts that Benefit People and the Planet

      SAN RAMON, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CooperCompanies ("Cooper") (NASDAQ:COO), a leading medical device company, published its 2024 Sustainability Report. The report showcases the company's initiatives to foster positive change for both people and the planet and provides expanded and updated sustainability performance data. In 2024, CooperCompanies maintained strong partnerships to reduce its plastic footprint, earned a number of sustainability certifications, and supported employee growth with significant investments in learning and development programs for employees. "Our 2024 Sustainability Report reflects Cooper's commitment to help people experience life's beautiful m

      5/20/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies to Participate in the William Blair Growth Stock Conference

      SAN RAMON, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today it will participate in the William Blair Growth Stock Conference on Thursday, June 5, 2025. Brian Andrews, Executive Vice President, Chief Financial Officer & Treasurer, will represent the Company in a session scheduled at 11:20 AM CT. The webcast will be available to investors and other interested parties by accessing the CooperCompanies' website at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two bu

      5/8/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care